SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission

Hamblin, Peter S, Wong, Rosemary, Ekinci, Elif I, Fourlanos, Spiros, Shah, Sonali, Jones, Alicia R, Hare, Matthew JL, Calder, Genevieve L, Epa, Dilan Seneviratne, George, Elizabeth M, Giri, Rinky, Kotowicz, Mark A, Kyi, Mervyn, Lafontaine, Nicole, MacIsaac, Richard J, Nolan, Brendan J, O'Neal, David N, Renouf, Debra, Varadarajan, Suresh, Wong, Jennifer, Xu, Sylvia and Bach, Leon A 2019, SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission, Journal of clinical endocrinology and metabolism, vol. 104, no. 8, pp. 3077-3087, doi: 10.1210/jc.2019-00139.

Attached Files
Name Description MIMEType Size Downloads

Title SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission
Author(s) Hamblin, Peter S
Wong, Rosemary
Ekinci, Elif I
Fourlanos, Spiros
Shah, Sonali
Jones, Alicia R
Hare, Matthew JL
Calder, Genevieve L
Epa, Dilan Seneviratne
George, Elizabeth M
Giri, Rinky
Kotowicz, Mark AORCID iD for Kotowicz, Mark A
Kyi, Mervyn
Lafontaine, Nicole
MacIsaac, Richard J
Nolan, Brendan J
O'Neal, David N
Renouf, Debra
Varadarajan, Suresh
Wong, Jennifer
Xu, Sylvia
Bach, Leon A
Journal name Journal of clinical endocrinology and metabolism
Volume number 104
Issue number 8
Start page 3077
End page 3087
Total pages 11
Publisher Oxford University Press
Place of publication Oxford, Eng.
Publication date 2019-08
ISSN 0021-972X
Keyword(s) Diabetic ketoacidosis (DKA)
Sodium glucose cotransporter 2 inhibitors (SGLT2is)
SGLT2 Inhibitors
Hospital Admission
Summary Context
Diabetic ketoacidosis (DKA) has been associated with the use of sodium glucose cotransporter 2 inhibitors (SGLT2is).

To determine the incidence, characteristics, and outcomes of DKA in SGLT2i users vs nonusers with type 2 diabetes.

Retrospective, multicenter, controlled cohort study.

All public hospitals in Melbourne and Geelong (combined population of 5 million), Australia, from 1 September 2015 to 31 October 2017.

Consecutive cases of DKA that developed in the community, or during the course of hospital admission, in patients with type 2 diabetes

Main Outcome Measures
In SGLT2i users vs nonusers: (i) OR of DKA developing during hospital admission, and (ii) incidence of DKA.

There were 162 cases of DKA (37 SGLT2i users and 125 non-SGLT2i users) with a physician-adjudicated diagnosis of type 2 diabetes. Of these, DKA developed during the course of inpatient admission in 14 (38%) SGLT2i users vs 2 (2%) non-SGLT2i users (OR, 37.4; 95% CI, 8.0 to 175.9; P < 0.0001). The incidence of DKA was 1.02 per 1000 (95% CI, 0.74 to 1.41 per 1000) in SGLT2i users vs 0.69 per 1000 (95% CI, 0.58 to 0.82 per 1000) in non-SGLT2i users (OR, 1.48; 95% CI, 1.02 to 2.15; P = 0.037). Fifteen SGLT2i users (41%) had peak blood glucose <250 mg/dL (14 mmol/L) compared with one (0.8%) non-SGLT2i user (P < 0.001).

SGLT2i users were more likely to develop DKA as an inpatient compared with non-SGLT2i users. SGLT2i use was associated with a small but significant increased risk of DKA.
Language eng
DOI 10.1210/jc.2019-00139
Indigenous content off
Field of Research 1103 Clinical Sciences
1114 Paediatrics and Reproductive Medicine
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2019, Endocrine Society
Persistent URL

Document type: Journal Article
Collections: Faculty of Health
School of Medicine
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 8 times in TR Web of Science
Scopus Citation Count Cited 11 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 103 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Thu, 11 Apr 2019, 15:31:10 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact